Cipla EU to invest EUR15 mn in Ethris

 Pharmaceutical firm Cipla on Friday announced that its wholly-owned UK subsidiary — Cipla EU — has signed definitive agreements for equity investment of EUR15 million in Ethris GmbH for the development of messenger RNA (mRNA)-based therapies.